Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2021 Nov 16;11:802949. doi: 10.3389/fonc.2021.802949

Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Alessio Bruni 1,*, Vieri Scotti 2, Paolo Borghetti 3, Stefano Vagge 4, Salvatore Cozzi 5, Elisa D’Angelo 1, Niccolò Giaj Levra 6, Alessandra Fozza 4, Maria Taraborrelli 7, Gaia Piperno 8, Valentina Vanoni 9, Matteo Sepulcri 10, Marco Trovò 11, Valerio Nardone 12, Elisabetta Lattanzi 13, Said Bou Selman 14, Federica Bertolini 15, Davide Franceschini 16, Francesco Agustoni 17, Barbara Alicja Jereczek-Fossa 8,18, Stefano Maria Magrini 3, Lorenzo Livi 2, Frank Lohr 1, Andrea Riccardo Filippi 19
PMCID: PMC8637883  PMID: 34869046

In the original article there was an error. The survival numbers were incorrect.

A correction has been made to Abstract:

“1-year PFS and OS were 83.5% (95%CI: 77.6-89.7) and 97.2% (95%CI: 94.6-99.9), respectively.”

“1-year PFS and OS were 65.5% (95%CI: 57.6-74.4) and 87.9% (95%CI: 82.26.6-93.9), respectively”

In the original article, there was an error. The survival numbers were incorrect.

A correction has been made to Results, Survival:

“PFS at 12, 18, and 24 months was 83.5% (95%CI: 77.6–89.7), 65.5 (95%CI: 57.6–74.4), and 53.1% (95%CI: 43.8–64.3), respectively. (Figure 1). OS at 12, 18, and 24 months was 97.2% (95%CI: 94.6– 99.9), 87.9% (95%CI: 82.26–93.9), and 79.3% (95%CI: 71.1–88.4), respectively (Figure 1).”

“PFS at 6, 12, and 18 months was 83.5% (95%CI: 77.6–89.7), 65.5% (95%CI: 57.6–74.4), and 53.1% (95%CI: 43.8–64.3), respectively. (Figure 1). OS at 6, 12, and 18 months was 97.2% (95%CI: 94.6– 99.9), 87.9% (95%CI: 82.26–93.9), and 79.3% (95%CI: 71.1–88.4), respectively (Figure 1)”

In the original article, there was an error. The survival numbers were incorrect.

A correction has been made to Discussion:

“12-month PFS was 83.5%, and OS 97.2%”

“12-month PFS was 65.5%, and OS 87.9%”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES